Buprenorphine (CODA/Suboxone) and Kidney Safety: Evidence Review

Buprenorphine (in CODA®, Suboxone®, Subutex®, Sublocade®, Brixadi®) has no evidence of direct nephrotoxicity at therapeutic doses for opioid use disorder (OUD).

Renal Pharmacology

  • Metabolism: Hepatic (CYP3A4 → norbuprenorphine); glucuronidation.
  • Excretion: Feces (70%), urine (30% as glucuronides).
  • No dose adjustment for renal impairment (including ESRD on dialysis).
  • Not dialyzable (high protein binding, large Vd).

Indirect Renal Considerations

  • Hepatitis C/HIV: Common in OUD → renal disease (MPGN, HIVAN).
  • Injection Drug Use: Abscesses, endocarditis → septic emboli, glomerulonephritis.
  • Rhabdomyolysis: From overdose/coma → AKI (not buprenorphine direct).
  • Dehydration: From withdrawal or poor self-care.

Clinical Monitoring

  • Baseline Cr, eGFR, UACR if risk factors.
  • Periodic monitoring per primary care — not buprenorphine-specific.
  • Dose adjustment not required for CKD/ESRD.

Common Side Effects (Non-Renal)

  • Constipation, nausea, headache, insomnia, sweating, sedation.
  • QTc prolongation (caution with other QT drugs).
  • Respiratory depression rare (partial agonist ceiling effect) — but ↑ with benzodiazepines/alcohol.

Buprenorphine is renal-safe. Kidney disease in OUD reflects comorbidities, not the medication. Continue OUD treatment — it reduces overdose mortality by 50–80%.

Kidney Disease - Related Articles